Demographic, clinical, and routine laboratory data of study participants
| Variable . | COVID-19 patients, n = 52 . |
|---|---|
| Age, y | 59 [49-63] |
| Female | 15 (28.8) |
| BMI, kg/m2 | 28.4 [24.7-32.4] |
| Comorbidity | |
| Cardiovascular | 8 (15.4) |
| Diabetes | 11 (21.2) |
| Renal dysfunction | 5 (9.6) |
| Symptom duration, d | 12 [8-15] |
| Duration of hospital stay, d | 6 [3-13] |
| Days between admission and first blood sample | 2 [2-3] |
| Location at time of first blood sample | |
| Ward | 47 (90.4) |
| Intermediate care unit | 4 (7.7) |
| Intensive care unit | 1 (1.9) |
| Respiratory requirements at time of first blood sample | |
| None | 20 (38.5) |
| Nasal cannula/mask ≤5 L O2 | 23 (44.2) |
| Nasal cannula/mask >5 L O2 | 9 (17.3) |
| Noninvasive ventilation | 1 (1.9) |
| Oxygen requirement, L/min | 1.3 [0.0-4.0] |
| Routine laboratory values at time of first blood sample | |
| Creatinine, mg/dL | 73 [64-90] |
| CRP, mg/dL | 98 [61-177] |
| Lactate, mg/dL | 1.35 [1.18-1.70] |
| WBC count, ×109/L | 6.5 [4.4-7.8] |
| Anticoagulation at time of first blood sample | |
| No | 10 (19.2) |
| Standard prophylactic LMWH, 4500 IU once daily | 27 (51.9) |
| Intermediate. prophylactic LMWH, 4500 IU twice daily | 15 (28.8) |
| Oral anticoagulant | 1 (1.9) |
| Anti-Xa, U/mL | 0.04 [0.00-0.07] |
| Anticoagulation at 4-mo follow-up | 4 (7.7)* |
| Venous thromboembolism during 4-mo follow-up | 1 (1.9) |
| Variable . | COVID-19 patients, n = 52 . |
|---|---|
| Age, y | 59 [49-63] |
| Female | 15 (28.8) |
| BMI, kg/m2 | 28.4 [24.7-32.4] |
| Comorbidity | |
| Cardiovascular | 8 (15.4) |
| Diabetes | 11 (21.2) |
| Renal dysfunction | 5 (9.6) |
| Symptom duration, d | 12 [8-15] |
| Duration of hospital stay, d | 6 [3-13] |
| Days between admission and first blood sample | 2 [2-3] |
| Location at time of first blood sample | |
| Ward | 47 (90.4) |
| Intermediate care unit | 4 (7.7) |
| Intensive care unit | 1 (1.9) |
| Respiratory requirements at time of first blood sample | |
| None | 20 (38.5) |
| Nasal cannula/mask ≤5 L O2 | 23 (44.2) |
| Nasal cannula/mask >5 L O2 | 9 (17.3) |
| Noninvasive ventilation | 1 (1.9) |
| Oxygen requirement, L/min | 1.3 [0.0-4.0] |
| Routine laboratory values at time of first blood sample | |
| Creatinine, mg/dL | 73 [64-90] |
| CRP, mg/dL | 98 [61-177] |
| Lactate, mg/dL | 1.35 [1.18-1.70] |
| WBC count, ×109/L | 6.5 [4.4-7.8] |
| Anticoagulation at time of first blood sample | |
| No | 10 (19.2) |
| Standard prophylactic LMWH, 4500 IU once daily | 27 (51.9) |
| Intermediate. prophylactic LMWH, 4500 IU twice daily | 15 (28.8) |
| Oral anticoagulant | 1 (1.9) |
| Anti-Xa, U/mL | 0.04 [0.00-0.07] |
| Anticoagulation at 4-mo follow-up | 4 (7.7)* |
| Venous thromboembolism during 4-mo follow-up | 1 (1.9) |
The results are presented as median [interquartile range] for continuous variables, and number (percentage) for categorical variables.
BMI, body mass index; CRP, C-reactive protein; LMWH, low-molecular-weight heparin; WBC, white blood cell.
Two of the 4 patients already received anticoagulation prior to hospital admission. The other 2 indications for anticoagulation were venous thromboembolism and atrial fibrillation.